The lawsuit contends that coordinated actions were designed to mislead, confuse, and gradually desensitize the public to anti-vaccine and anti-science rhetoric.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
At a routine press briefing today, two White House officials fielded questions about President Joe Biden's recent off-the-cuff comment during a news program that the pandemic is over, while acknowledging that COVID is still a problem.
Healthcare workers in lower-paying roles, however, were more likely to face unemployment.
The comments prompted swift and sharp criticism among some public health experts.
"We think these principles can be applied to the next respiratory viral epidemic," a committee chair said of the SHEA statement.
Moderna's 2-strain booster triggered stronger antibody responses that its original booster did.
About 9 months after COVID-19 infection, 19% of nonhospitalized adult patients in a German cohort had fatigue, 26% had mild cognitive impairment ("brain fog"), and 1% had moderate cognitive dysfunction, according to a multicenter study.
The study, published late last week in EClinicalMedicine, also showed that the incidence and risk factors for fatigue and cognitive impairment differed by age-group.
One in three unvaccinated COVID-19 survivors in a Spanish cohort had no detectable SARS-CoV-2 antibodies nearly 1 year after infection, according to a prospective study published today in BMC Medicine.
After 2 years, 12% had lingering symptoms and 8% had new-onset or worsening symptoms.
The report spares no one the responsibility—including the public—for millions of preventable deaths.
South African researchers report waning monovalent (single-strain) COVID-19 vaccine booster effectiveness against the Omicron subvariants, with estimated efficacy falling to 50% against the BA.1/BA.2 and 47% against BA.4/BA.5 as early as 3 or 4 months after vaccination.
